Michelle Lock
Direktor/Vorstandsmitglied bei RELIEF THERAPEUTICS HOLDING SA
Vermögen: - $ am 31.05.2024
Profil
Michelle Lock is currently a Director at RELIEF THERAPEUTICS Holding SA. She previously worked as a Senior Vice President, Head-Europe & International at Acceleron Pharma, Inc. and as a Chief Operating Officer at Covis Pharma Holdings BV.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 30.04.2024 | 0 ( -.--% ) | - $ | 31.05.2024 |
Aktive Positionen von Michelle Lock
| Unternehmen | Position | Beginn |
|---|---|---|
| RELIEF THERAPEUTICS HOLDING SA | Direktor/Vorstandsmitglied | 28.01.2022 |
Ehemalige bekannte Positionen von Michelle Lock
| Unternehmen | Position | Ende |
|---|---|---|
Covis Pharma Holdings BV
 Covis Pharma Holdings BV Pharmaceuticals: MajorHealth Technology Covis Pharma Holdings BV engages in the marketing and distribution of therapeutic solutions for patients with life-threatening conditions and chronic illnesses. It offers its products under the Alvesco, Omnaris, Zetonna, Altoprev, Betapace, Betapace AF, Lanoxin, Sular, Prilosec, Zanaflex, Rilutek, Tizanidine Hydrochloride, Nisoldipine, and Riluzole brands. The company was founded in December 2011 and is headquartered in Zug, Switzerland. | Geschäftsführer | - |
| ACCELERON PHARMA INC. | Corporate Officer/Principal | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| RELIEF THERAPEUTICS HOLDING SA | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Acceleron Pharma, Inc.
 Acceleron Pharma, Inc. BiotechnologyHealth Technology Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis on June 13, 2003 and is headquartered in Rahway, NJ. | Health Technology |
Covis Pharma Holdings BV
Covis Pharma Holdings BV Pharmaceuticals: MajorHealth Technology Covis Pharma Holdings BV engages in the marketing and distribution of therapeutic solutions for patients with life-threatening conditions and chronic illnesses. It offers its products under the Alvesco, Omnaris, Zetonna, Altoprev, Betapace, Betapace AF, Lanoxin, Sular, Prilosec, Zanaflex, Rilutek, Tizanidine Hydrochloride, Nisoldipine, and Riluzole brands. The company was founded in December 2011 and is headquartered in Zug, Switzerland. | Health Technology |
